# Role of Leptin in the Neuroendocrine and Immune Response to Fasting

> **NCT00140231** · PHASE1,PHASE2 · COMPLETED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 13 (actual)

## Conditions studied

- Fasting

## Interventions

- **DRUG:** r-metHuLeptin
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00140231
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2011-03
- **Final completion:** 2016-12
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2017-06-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00140231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00140231, "Role of Leptin in the Neuroendocrine and Immune Response to Fasting". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00140231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*